Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder
About Clarus Therapeutics Holdings, Inc.Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022
法院監督的JATENZO(十一酸睾酮膠囊；C-III)拍賣於2022年10月14日結束
NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Bankruptcy Court for the District of Delaware [Docket No. 78] and the sale of JATENZO remains subject to final Bankruptcy Court approval on October 26, 2022.
諾斯布魯克，伊利諾伊州，2022年10月18日(Global Newswire)-克拉魯斯治療控股公司(Clarus Treateutics Holdings，Inc.)(場外交易代碼：CRXTQ)是一家致力於通過推進雄激素治療為未滿足的醫療需求提供解決方案的製藥公司，該公司今天宣佈，根據最終文件的要求，它及其全資子公司Clarus治療公司選擇Tolmar，Inc.(布法羅格羅夫，伊利諾伊州)作為JATENZO(和某些相關資產)出售的競爭性招標和拍賣程序的中標人。競標和拍賣程序得到了特拉華州地區美國破產法院的批准[案卷第78號]JATENZO的出售仍有待破產法院2022年10月26日的最終批准。
Additional information about this asset sale, as well as other documents related to the Chapter 11 proceedings, is available through Clarus' claims agent, Stretto, Inc., available at: Clarus' legal counsel is Goodwin Procter, LLP and Potter Anderson & Corroon LLP, and its investment banker is Raymond James & Associates, Inc. Lawrence Perkins of Sierra Constellation Partners, LLC currently serves Clarus as Chief Restructuring Officer during the Chapter 11 process. Clarus filed the voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the District of Delaware, Case No. 22-10845 (MFW).
有關此次資產出售的更多信息以及與破產法第11章訴訟有關的其他文件，可以通過Clarus的索賠代理人Stretto公司獲得，網址是：Clarus的法律顧問是Goodwin Procter LLP和Potter Anderson&Corroon LLP，其投資銀行家是Raymond James&Associates，Inc.目前Clarus擔任破產法第11章過程中的首席重組官。Clarus向特拉華州地區美國破產法院提交了自願破產申請，案件編號22-10845(MFW)。
About Clarus Therapeutics Holdings, Inc.
克拉魯斯治療控股公司簡介
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen-based medicines. Clarus Therapeutics' first commercial product is JATENZO (testosterone undecanoate capsules; C-III). For more information, visit and . Follow Clarus on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).
Clarus Treateutics Holdings，Inc.是一家在開發雄激素藥物方面擁有專業知識的製藥公司。Clarus治療公司的第一個商業產品是JATENZO(十一酸睾酮膠囊；C-III)。有關更多信息，請訪問和。在Twitter(@Clarus_Thera)和LinkedIn(Clarus Treeutics)上關注Clarus。
Forward-Looking Statements
前瞻性陳述
Certain statements in this press release constitute "forward-looking statements" for purposes of the federal securities laws. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Clarus' forward-looking statements in this press release include, but are not limited to, statements about Clarus' plans to sell all of its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code; Clarus' intention to enter into a definitive documentation for the asset sale; Court approval of the asset sale and timing thereof among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Clarus will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Clarus' control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with negotiating a definitive asset purchase agreement, risks associated with Court approval of the terms and ability to meet the closing conditions, along with the risks associated with the potential adverse impact of the Chapter 11 filings on Clarus' liquidity and results of operations; changes in Clarus' ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations; the outcome and timing of the Chapter 11 process and the proposed asset sale; the effect of the Chapter 11 filings and proposed asset sale on Clarus' relationships with vendors, regulatory authorities, employees and other third parties; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the proposed asset sale; and the timing or amount of any distributions, if any, to Clarus' stakeholders, as well as risks associated with pharmaceutical development and being a pharmaceutical company generally, along with those factors described under the heading "Risk Factors" in Clarus' annual report on 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (the SEC) on March 31, 2022, and those that are included in any of Clarus' future filings with the SEC. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic and there may be additional risks that Clarus considers immaterial, or which are unknown. It is not possible to predict or identify all such risks. Clarus' forward-looking statements only speak as of the date they are made, and Clarus does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
就聯邦證券法而言，本新聞稿中的某些陳述構成“前瞻性陳述”。詞語“預期”、“相信”、“考慮”、“繼續”、“可能”、“估計”、“預期”、“打算”、“可能”、“可能”、“計劃”、“可能”、“潛在”、“預測”、“項目”、“應該”、“將會”、“將會”以及類似的表述可以識別前瞻性陳述。但沒有這些話並不意味着一份聲明不具有前瞻性。Clarus在本新聞稿中的前瞻性陳述包括但不限於有關Clarus根據美國破產法第11章出售其所有資產的計劃、Clarus打算就資產出售達成最終文件、法院批准資產出售及其時間等的陳述。這些前瞻性陳述是基於對未來發展及其潛在影響的當前預期和信念。不能保證影響克拉魯斯的未來事態發展會如預期的那樣。這些前瞻性陳述涉及許多風險、不確定性(其中一些是Clarus無法控制的)或其他假設，可能導致實際結果或表現與這些前瞻性陳述明示或暗示的大不相同。這些風險和不確定性包括但不限於與談判最終資產購買協議相關的風險、與法院批准條款相關的風險以及滿足成交條件的能力, 以及與破產保護申請對Clarus的流動性和經營結果的潛在不利影響相關的風險；Clarus在破產保護過程中履行其財務義務並維持對其運營至關重要的合同的能力的變化；破產保護申請和擬議的資產出售的結果和時機；破產保護申請和擬議的資產出售對Clarus與供應商、監管機構、員工和其他第三方的關係的影響；第三方可能就破產程序或擬議的資產出售提起的訴訟；以及向Clarus的利益相關者分發任何產品的時間或金額(如果有的話)、與藥物開發相關的風險和作為一家制藥公司的一般情況，以及在Clarus於2022年3月31日提交給美國證券交易委員會(The Securities and Exchange Commission，簡稱：美國證券交易委員會)的截至2021年12月31日的10-K年度報告中“風險因素”標題下描述的那些因素，以及Clarus未來提交給美國證券交易委員會的任何文件中包含的那些因素。其中一些風險和不確定性在未來可能會被正在進行的新冠肺炎大流行放大，可能會有更多的風險被Clarus認為是無關緊要的，或者是未知的。不可能預測或識別所有此類風險。除了適用的證券法可能要求的情況外，Clarus的前瞻性陳述僅在作出陳述之日發表，不承擔任何因新信息、未來事件或其他原因而更新或修改任何前瞻性陳述的義務。
JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc. Source: Clarus Therapeutics Holdings, Inc.
JATENZO®是克拉魯斯治療控股公司的註冊商標。
Media and Investor Contact
媒體和投資者聯繫方式
Steve Bourne
史蒂夫·伯恩
Chief Financial Officer
首席財務官
Sbourne@clarustherapeutics.com
郵箱：sbourne@clarusTreateutics.com
譯文內容由第三人軟體翻譯。
